What does the evidence say about Spirulina Cholesterol Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Spirulina Cholesterol Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 3 4 2 2 2 Obesity constitutes a major global health concern, closely associated with a range of metabolic dysfunctions such as insulin resistance, dyslipidemia, and chronic systemic inflammation. [Yasul Yavuz (2026); evidence level 1] - These dysfunctions significantly elevate the risk of developing type 2 diabetes, cardiovascular disease, and other metabolic syndromes, underscoring the need for comprehensive and integrative interventions [,]. [Yasul Yavuz (2026); evidence level 1] - According to the World Health Organization (WHO), individuals with a body mass index (BMI) ≥ 25 kg/m, encompassing both overweight (25.0–29.9 kg/m) and obese (≥30.0 kg/m) categories, are at increased cardiometabolic risk and were therefore included in this systematic review. [Yasul Yavuz (2026); evidence level 1] - 14 8 9 15 16 16 17 Its cultivation advantages, such as growth in alkaline environments, reduced freshwater demand, and relatively low production costs, further strengthen its sustainability profile (). [Ibrahim Marwa Ezz El-Din (2026); evidence level 3] - By synthesizing recent evidence, this study seeks to clarify the current state of development, identify research gaps, and provide a comprehensive framework for future research and industrial implementation. [Ibrahim Marwa Ezz El-Din (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.